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Key messages 
 
 Formal and transparent discussion of multiple viewpoints, interests and priorities facilitates mutual 
understanding of complex decision problems 
 Benefit-risk assessments of treatments should be undertaken in a structured way so that it is clear how a 
decision on the overall balance of a treatment’s effects has been reached 
 Various structured approaches and singular methodologies/visual representations are available to support 
benefit-risk assessment of medicines, but so far universal agreement as to the most suitable method for 
structured benefit-risk assessment has been lacking 
 A team combining expertise from public and private institutions carried out a review of benefit-risk methods 
and visual representations, including application of the tools to case studies based on real regulatory 
scenarios 
 The project produced a clear set of practical recommendations for undertaking benefit-risk assessments, 
organised around a generic, five stage benefit-risk assessment roadmap 
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Abstract 
Purpose 
To draw on the practical experience from the PROTECT BR case studies and make recommendations regarding the 
application of a number of methodologies and visual representations for benefit-risk assessment. 
Methods 
Eight case studies based on the benefit-risk balance of real medicines were used to test various methodologies that 
had been identified from the literature as having potential applications in benefit-risk assessment.  
Recommendations were drawn up based on the results of the case studies. 
Results 
A general pathway through the case studies was evident, with various classes of methodologies having roles to play 
at different stages.  Descriptive and quantitative frameworks were widely used throughout to structure problems, 
with other methods such as metrics, estimation techniques and elicitation techniques providing ways to incorporate 
technical or numerical data from various sources.  Similarly, tree diagrams and effects tables were universally 
adopted, with other visualisations available to suit specific methodologies or tasks as required.  Every assessment 
was found to follow five broad stages: 1) Planning, 2)Evidence gathering and data preparation, 3) Analysis, 4) 
Exploration, and 5) Conclusion and dissemination. 
Conclusions 
Adopting formal, structured approaches to benefit-risk assessment was feasible in real-world problems and 
facilitated clear, transparent decision making. Prior to this work, no extensive practical application and appraisal of 
methodologies had been conducted using real world case examples, leaving users with limited knowledge of their 
usefulness in the real world.  The practical guidance provided here takes us one step closer to a harmonised 
approach to benefit-risk assessment from multiple perspectives.  
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Introduction 
Benefit-risk assessments play a critical role in bringing treatments to market, providing crucial information for 
decisions regarding (among others) drug development, licensing and reimbursement.  In such situations, judgements 
by individuals or committees have traditionally been the main approach.  However, without an explicit, systematic 
framework to capture the logic around these assessments, there has been increasing concern among companies and 
regulators about non-standardised, implicit and often qualitative approaches, with the Council for International 
Organizations of Medical Sciences (CIOMS) IV suggesting that explicit, quantitative statements would improve the 
transparency and consistency of decisions.1  It was this concern that led the European Medicines Agency to establish 
the three-year Benefit-Risk Methodology Project in 2009,2 and the ongoing testing of tools and processes for 
balancing the key benefits and risks of a new medicinal product.3  In the US since 2010, the Food and Drug 
Administration and industry worked together to introduce a formal framework for benefit-risk assessment into the 
reauthorization of the Prescription Drug User Fee Act.4 
Various structured approaches to decision-making have been developed and widely employed in other fields to 
address similar problems, and many could theoretically be applied in benefit-risk assessment to address concerns 
about the decision-making process.  However, these have not traditionally been used in this field, and no single 
agreed method exists for integrating benefit-risk data or to determine the overall balance, and hence arrive at a 
treatment decision. Importantly, while several methodologies had been proposed prior to this project, a thorough 
appraisal of methodologies and practical applications in a large number of different real-life case studies had been 
missing, leaving practitioners with limited guidance. 
The Innovative Medicines Initiative’s PROTECT project (Pharmacoepidemiological Research on Outcomes of 
Therapeutics by a European ConsorTium) was established with the aim of strengthening the monitoring of the 
benefit-risk balance of medicines in Europe.  This paper reports the findings of PROTECT’s Benefit-Risk Group 
(PROTECT BR) since inception in September 2009.  The group’s objectives were to: “1) identify, characterise and test 
methods of collating data on benefits and risks from various data sources, parameters and strengths of evidence, 
and of integrating them with decision-criteria and formal assessment of values of patients, healthcare providers, 
regulators, the pharmaceutical industry and in benefit-risk assessment; 2) identify, test and compare modelling 
approaches that would allow continuous benefit-risk risk-modelling along the lifecycle of the product, and support 
decision-making; and 3) develop methods of graphical expression of the benefits and risks of the medicinal products 
for use by patients, healthcare providers, the pharmaceutical industry and regulators along the lifecycle of the 
product”5.  A variety of organisations from the public, private and academic sectors participated in the group. 
A total of thirteen methodologies with features representative of their categories were selected for investigation in 
the case studies.  This list was not intended to be exhaustive or restrictive, but it was believed that, taken together, 
the selected methodologies would be a sufficiently powerful toolbox for most benefit-risk assessments.6  The 
thirteen methodologies, their classification and the abbreviations used to refer to them are shown in Table 1. 
Due to the limited space available for the main text of this paper, a degree of familiarity with the names and basic 
features of the methods and visualisations is assumed on the part of the reader.  For those with no knowledge of the 
methods, a description of each method and visual type is provided in the Appendices.  The purpose of this paper is 
to augment the existing descriptions and theoretical appraisals of these benefit-risk assessment methods and visual 
representations with practical experience and recommendations from the PROTECT BR case studies. 
<<Table 1 here>> 
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Methods 
The case studies were selected based on real world scenarios involving medicines where the publicly available data 
suggested a marginal benefit-risk balance and which presented various practical challenges to stress-test candidate 
methods. The drugs and indications that formed the focus of the case studies are shown in Table 2.  The methods 
were tested in two ‘waves’ comprising four case studies each. The first wave established the feasibility of many 
candidate methods by applying them to a straightforward benefit-risk assessment problem, while the second 
explored more complex scenarios or methods, and applied selected visual representation techniques.  Each case 
study was highly collaborative in nature, with participants drawn from the range of public and private organisations 
within PROTECT BR.  The case study teams worked independently of each other, but some individuals worked on 
more than one case study. 
<<Table 2 here>> 
The case study teams used only publicly available evidence on treatment effects.  The qualitative and quantitative 
methods applied throughout the case studies drew heavily on the principles of decision analysis, which provided the 
foundations for both the BRAT and PrOACT-URL frameworks, and the theory underlying the most frequently used 
quantitative approach, MCDA, was used in some form in all of our case studies.   
Following the case studies, the key findings and lessons learnt from the reviews and case studies were organised 
according to five stages representing an approximate chronological order of activities to be undertaken for a benefit-
risk assessment (the Recommendations Roadmap), which aims to provide an overarching view of benefit-risk 
assessment for those who are new to the process, while also allowing more experienced readers to hone in on 
technical aspects or methodologies of interest.41 
The efalizumab study has been chosen to provide the illustrations in this paper as it has features that were shared by 
many of the case studies, is comprehensive enough to illustrate a range of approaches and provides visual examples 
that are relatively simple. 
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Results 
Case studies 
Each of the eight case studies applied several methodologies in combination or in parallel, as shown in Table 1. In 
total, ten of the thirteen methodologies recommended by Mt-Isa et al6 were tested; no suitable data could be found 
for the QALY, Q-TWiST or INHB methodologies in any case study.  Two additional quantitative frameworks were also 
tested:  weighted Net Clinical Benefit42 (wNCB) in the natalizumab case study and Sarac’s Benefit-Risk Assessment 
Method43 (SBRAM) in the telithromycin case study.  wNCB is a utility-weighted extension of NNT/NNH, and can be 
seen as a special case of MCDA that is simpler to apply in some situations. SBRAM has a similar structure to the other 
frameworks but with a unique way of scoring the data on each treatment effect.   
Methods were chosen according to their suitability for the underlying decision problem and compatibility with the 
available data (for example, some methods such as NNT/NNH only work with binary outcome data).  Methods were 
selected by group consensus within the case study teams; it is acknowledged that individuals may have proposed 
methods based on their own experience or research interests.  In the first wave of case studies, teams were required 
to use as many methods as possible, giving reasons for any excluded methods, in order to encourage a 
comprehensive evaluation. The reasons given for selecting or excluding each method at this stage are set out in 
Appendix 2 and summarised in Table 1.   Each case study in the second wave, by contrast, was aimed at testing a 
particular method or subset of methods as indicated in Appendix 3. 
A common structure to the case studies emerged, with each team using a descriptive (i.e. qualitative) framework to 
document key contextual aspects of the benefit-risk assessment and to act as a foundation and a guide for the 
application of formal methods for specific subtasks, namely: measuring/expressing outcomes (metrics), extracting 
data (estimation techniques), eliciting preferences (utility survey techniques) and integrating effects data with 
preferences (quantitative frameworks).  This common structure is shown in Figure 1.  
<<Figure 1 here>> 
A common pathway through each case study also emerged, with each team proceeding in broadly the following 
order: 
1. select a descriptive framework 
2. consider and document basic aspects of the decision context, beginning with a statement of the decision 
question itself in fairly general terms and moving towards more specific practical aspects of the problem 
such as establishing what alternative treatments exist and what data are available 
3. examine the data and establish what metrics could be used to express the favourable and unfavourable 
effects 
4. extract the data in the desired form using estimation techniques 
5. optionally, elicit preference information using utility survey techniques and integrate this with the effects 
data using a quantitative framework 
6. bring the results of the previous step back into the descriptive framework  and proceed to conduct sensitivity 
analyses and communicate the findings. 
This critical path is shown on Figure 1 by the curved arrow.  It is important to note that, although this indicates the 
general order in which to proceed, the teams often found that it was necessary to look a few steps ahead during the 
process and/or to revisit earlier tasks in the light of what was uncovered later (for example, the choice of 
quantitative framework could in some cases limit the range of metrics that could be adopted).  The next few 
paragraphs deal with each step of the path in turn. 
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The descriptive frameworks PrOACT-URL and BRAT were found to be useful guides for planning and executing a 
benefit-risk assessment and are considered suitable for use at any stage of a medicinal product’s life cycle.  Each was 
used in six out of the eight case studies, with the first wave of four case studies employing both frameworks in 
parallel.  The frameworks provide a structure for breaking down a benefit-risk problem into a stepwise thought 
process.  The list of steps is somewhat similar in both frameworks, although they do not perfectly map onto one 
another.   At the time of the initial methodology review, PrOACT-URL and BRAT were the two most promising 
descriptive frameworks; other frameworks may have since emerged, but we have not reviewed these and are unable 
to comment on their suitability. 
The descriptive frameworks encourage clear delineation of the decision problem, which in the benefit-risk context 
means setting out the treatment under investigation, the indication and target population of interest, and any 
specific efficacy or safety concerns that have prompted the assessment.   Clinical expertise can then guide the choice 
of appropriate comparators, i.e. existing alternative treatments that act as benchmarks for the benefit-risk balance. 
The favourable and unfavourable effects in the assessment should include, at a minimum, key efficacy measures, any 
adverse events that may have prompted the assessment, and the key side effects of the treatment under 
investigation and of all the comparators.  In practice, our case study teams found selecting a complete set of relevant 
effects to be a surprisingly difficult task.  The assessor typically starts with an exhaustive list of clinical outcomes for a 
given treatment and indication, and must attempt to narrow this down to those benefits and risks that have a 
substantial impact on the benefit-risk balance, aiming to represent the range of treatment effects as fully as possible 
while avoiding problems such as double-counting of endpoints44.  The effects are often displayed in a tree diagram or 
value tree such as that shown in Figure 2, which is a simplified version of the final tree from the efalizumab case 
study.   Such tree diagrams can be used with any methodology that handles multiple outcomes in order to aid 
understanding of the structure of the problem, and are typically drawn up in the early stages of the PrOACT-URL or 
BRAT frameworks and/or used to guide the weighting process in quantitative methods such as MCDA.   To avoid 
bias, decision-makers should establish a common understanding and state the assumptions underlying the selection 
of benefits and risks.  This allows for a transparent and auditable selection process.  Ideally, both clinical expertise 
and patients’ views inform selection of the most relevant benefits and risks, and sufficient time should be allowed to 
resolve any disagreements through group discussion.   
<<Figure 2 here>> 
Our case studies were retrospective in nature and used publicly available data, principally from published trial 
reports and public registration documents (such as European public assessment reports and periodic safety update 
reports in the European Union, or periodic adverse drug experience reports in the United States), which are a 
convenient summary of the data from pivotal studies allowing replication and further exploration by others.  
However, these documents have clear limitations for benefit-risk assessment. They are low on detail, and reporting 
standards and outcome definitions frequently vary.   In some cases, to facilitate testing of the more complex 
methods, the teams made strong modelling assumptions on an ad hoc basis to align the data (for example, to 
convert between related outcome measures where the same measure was not reported for all comparators). We 
recognise that this may have introduced bias in some instances and that real-world assessors would need to proceed 
more carefully with any data manipulations, or to use more qualitative methods and avoid the problem altogether.  
Nevertheless, we feel our approach was justified for the purpose of this project, which was to test methodologies 
rather than comment on the benefit-risk balance of medicines.   
Metrics are measures used to numerically express the absolute or relative value of treatment effects.  This includes 
everyday outcome measures such as incidence rates, which were not specifically reviewed by PROTECT-BR owing to 
their familiarity and ubiquity in medical reporting, but were nevertheless indispensable in the case studies.  The 
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group of metrics known as Impact Numbers go further in describing the numbers of people affected by (binary) 
events in a population, but were not found to be particularly useful for making benefit-risk decisions.  The NNT/NNH 
and BRR metrics were developed to compare multiple effects for benefit-risk assessment, but in their standard form 
they suffer from being able to compare only one favourable and one unfavourable effect, and from not explicitly 
acknowledging any difference in importance between the effects (even, arguably, implying they are of equal 
importance).   To address these shortcomings, extensions to NNT/NNH have been developed, effectively resulting in 
the wNCB quantitative framework which is discussed below. 
Estimation techniques are designed to facilitate the extraction and/or synthesis of appropriate values for the chosen 
metrics.  Again, widely known epidemiological/biostatistical methods such as 2x2 tables or meta-analyses can be 
seen to fall within this class but have not been evaluated by PROTECT BR owing to their familiarity.  The two specific 
estimation techniques evaluated were ITC/MTC and PSM, and both were found particularly useful in the case studies 
as they lend themselves naturally to benefit-risk assessments.   ITC/MTC is designed to bring together evidence on 
several treatments where each source study does not compare all treatments simultaneously, a situation that arose 
in both the natalizumab and rimonabant case studies.  PSM is used to propagate uncertainty through complex multi-
variable models, and as such was the only tool capable of quantifying the uncertainty of the overall benefit-risk 
balance in many of the case studies. 
Quantitative frameworks integrate objective treatment effects data with subjective preference data, i.e. utilities 
and/or weights that give information regarding the relative importance of the treatment effects.   MCDA was the 
most commonly used quantitative framework in the case studies, owing partly to its comprehensiveness, flexibility 
(unlike some other methods it is not restricted in the types of outcome metrics it can handle) and its natural link 
with the PrOACT-URL descriptive framework.  SMAA was also used widely in the case studies; this method is an 
extension of MCDA that explores all possible weightings in the event that utility/preference information is missing or 
limited, essentially applying PSM to the weights in an MCDA model.  This is certainly a useful tool, but we would not 
recommend it as the default approach; it would be a shame if most benefit-risk assessments employed quantitative 
decision models and yet made no attempt to understand the underlying trade-offs.  Also evaluated were wNCB, a 
weighted extension of the NNT/NNH metric and which is similar to MCDA but limited to binary outcomes, and 
SBRAM, which is again similar to MCDA but uses a simplified scoring system that does not always discriminate well 
between different options. 
Utility survey techniques are used to obtain utility/preference information for use in a quantitative framework.  
MCDA is usually implemented via a simple pairwise weighting process whereby stakeholders directly quantify the 
importance of outcomes (“swing weighting”), but the rimonabant case study also combined MCDA with DCE, a utility 
survey technique that presents participants with a set of binary choice scenarios in which the outcomes take 
different values.  For simple problems, a well-designed DCE with a sufficiently large number of responses can 
arguably provide the most comprehensive preference information, but DCEs require significant resources to design, 
and it has been argued that they do not work well when more than seven outcomes are to be considered 
simultaneously (a limit that was exceeded in most of our case studies).  Swing weighting is more easily adaptable to 
different problems and was therefore favoured in the case studies. 
The reports available at http://www.imi-protect.eu/benefitsRep provide detailed accounts of the application of the 
methods to the case study problems.  This paper includes several examples from the efalizumab case study which 
asked, hypothetically, whether the overall benefit-risk balance of the drug as a treatment for chronic plaque 
psoriasis was favourable based on publicly available data at the time of regulatory review. However, this work was 
intended to test methodologies and representations for the evaluation of benefit and risk of medicines. It neither 
replaces nor is intended to replace or comment on any regulatory decisions made by national regulatory agencies, 
nor the European Medicines Agency. 
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Appraisal of visual representations 
Among the variety of visual representations applied throughout the case studies, two visual types stood out as 
playing a fundamental role in every assessment.  These are the value tree (or tree diagram) (Figure 2) and effects 
table (or data table) (Table 3) (examples taken from the efalizumab case study).  The value tree is a simple visual 
hierarchy that displays the favourable and unfavourable effects (with clear definitions provided) and organises them 
into smaller groups to aid understanding (by adopting a logical structure based on, say, body systems) and/or 
facilitate elicitation of preferences (by grouping together outcomes according to seriousness, duration or any other 
factor that aids comparison). 
<<Table 3 here>> 
The effects table also lists the favourable and unfavourable effects, not necessarily grouped this time but with the 
numerical values of the outcome metrics for each comparator and other key data clearly displayed in each row.  The 
data shown in the effects table is purely descriptive, i.e. it does not incorporate any in-depth analysis or preference 
information.  The effects table is an important milestone in a benefit-risk balance because it summarises all the 
objective data and prompts the assessor to consider what more is required.  The data may clearly show that one 
treatment has a superior benefit-risk balance than all its comparators.  If, alternatively, the data in the effects table 
shows no clear advantage for any one treatment then quantitative modelling of the benefit-risk balance (i.e. 
assigning preferences to the treatment effects) may be considered, either on a fully quantitative basis (with explicit 
utilities) or a partially quantitative one (a complete or partial ranking of the treatment effects that eliminates any 
doubt as to the overall balance).  Figure 3 is a flowchart showing the possible ways in which a benefit-risk 
assessment may proceed at this point. 
<<Figure 3 here>> 
Besides the value tree and effects table, a variety of other visual types were used in the case studies.  Figures 4 and 5 
are a difference display and a line graph from the efalizumab case study, showing, respectively, the results of a 
quantitative analysis using MCDA and a sensitivity analysis on a key preference parameter.   
PROTECT BR’s visual review workstream investigated visuals in greater depth, identifying 14 visual types. The team 
made recommendations on how to create these visuals by considering four audience-visual compatibility criteria, 
and how to determine appropriate visuals for benefit-risk information through a series of key benefit-risk questions. 
Further recommendations on visuals, including their style and design, were published in a full report45 and in another 
article46.  More details, including interactive visual displays created within PROTECT BR’s case studies, are available at 
http://protectbenefitrisk.eu/visualisations.html.  
<<Figure 4 here>> 
<<Figure 5 here>> 
Recommendations and Conclusions 
The critical path through a benefit-risk assessment shown in Figure 1 can be organised according to five broad stages 
common to all benefit-risk assessments:41  1) Planning, 2) Evidence Gathering and Data Preparation, 3) Analysis, 4) 
Exploration and  5) Conclusion and Dissemination, as shown in Figure 6 with key recommendations for each stage. 
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<<Figure 6 here>> 
 
Regulators, such as the European Medicines Agency, and pharmaceutical companies have begun implementing 
structured approaches to benefit-risk assessments, but each organisation has adopted its own set of frameworks 
and tools, leading some commenters to propose a harmonisation initiative.1, 47, 48  It is clear that many of the 
frameworks and methods have common elements; identifying these and finding a shared, transparent language to 
describe them is arguably more realistic than finding a one-size-fits-all approach to benefit-risk assessment.  
PROTECT BR has stopped short of recommending outright any particular framework or methodology, emphasising 
instead the importance of a structured approach with careful planning and execution.  The resulting 
recommendations provide guidance on the tools available for benefit-risk assessment as the discipline evolves and a 
more harmonised approach begins to emerge. We suggest that techniques reviewed by this project lend themselves 
to the inclusion of stakeholders who bring many perspectives and whose input can be included systematically, in 
qualitative and quantitative ways, to enhance the overall benefit-risk assessment.  We strongly encourage the use of 
structured approaches to provide added clarity around the assessment of favourable and unfavourable effects of 
medicines. 
Unanswered questions and ongoing research 
The scope of this project was limited in that all case studies refer to pharmaceutical prescription medicines. Vaccines 
and over-the-counter medicines were not evaluated and may require different techniques. The usefulness of 
methodologies recommended by PROTECT BR for the benefit-risk evaluation of vaccines is being evaluated within 
IMI ADVANCE49. 
One theme whose importance has become apparent during the project is patient and public involvement (PPI) in 
benefit-risk assessment: It is possible that the benefit-risk balance of a treatment may vary depending on whose 
perspective is adopted, and there is a strong case for representing all stakeholders in the assessment process.  There 
is work to be done to establish the extent to which PPI in benefit-risk assessment is desirable/feasible and to test 
specific methods for its application.  
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 Description Features Rationale for use 
Frameworks 
PrOACT-URL7,8 Problem, Objectives, 
Alternatives, 
Consequences, Trade-
offs, Uncertainty, Risk, 
and Linked decisions  
A structured, qualitative approach, 
based on decision theory, of issues 
to consider in assessing the benefit-
risk balance of a drug and its 
comparator(s).  
All models used either PrOACT-URL 
or BRAT, or both, to guide the 
modelling process. They are similar 
in contributing transparency and 
structure to the benefit-risk 
balance.  For the Warfarin team, 
BRAT helped to identify relevant 
clinical effects and to visualise 
magnitudes. The Rimonabant team 
found PrOACT-URL to be more 
comprehensive, and for the 
Rosiglitazone team, it encouraged 
a focus on value trade-offs.  
BRAT9,10 Benefit Risk Action 
Team  
A structured, qualitative approach to 
assessing benefit-risk, based on 
MCDA, similar to PrOACT-URL, and 
supported by a set of guidelines and 
a tool. 
MCDA11-13 Multi Criteria Decision 
Analysis 
A quantitative methodology for 
integrating multiple benefit and risk 
criteria for a drug and its 
comparator(s), to provide for each 
option an index of the benefit-risk 
balance.  
All teams chose MCDA in both 
waves (SMAA for warfarin) because 
of its comprehensiveness, 
accommodation of any effect 
metrics and value judgements, and 
support for trade-off weighting, all 
requirements for a fully 
quantitative model. 
SMAA14-16 Stochastic Multi-
criteria Acceptability 
Analysis 
An extension of MCDA that formally 
incorporates uncertainty by 
replacing point estimates of a drug’s 
effects with probability distributions. 
The Telithromycin, Rimonabant 
(wave 2) and Warfarin teams chose 
SMAA so they could explicitly 
model uncertainty and explore the 
effects of different weighting 
systems. 
Metrics 
NNT/NNH17,18 Number Needed to 
Treat/Number Needed 
To Harm 
The reciprocal of the difference in 
proportions of patients experiencing 
a given effect between the 
treatment and control group. 
Only rimonabant (wave 1) explored 
NNT/NNH and Impact Numbers 
because they are simple ways to 
communicate a single effect. They 
are not recommended as general 
tools for benefit-risk assessment 
because they do not consider the 
clinical relevance of the effects nor 
are trade-offs between effects 
considered. 
IN19-22 Impact Numbers An extension of NNT that takes 
account of the population being 
represented and other aspects of 
context. 
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 Description Features Rationale for use 
BRR23-25 Benefit Risk Ratio The ratio of the magnitude of the 
most beneficial favourable effect to 
the magnitude of the most 
unfavourable effect. 
Efalizumab, Telithromycin and 
Rimonabant (wave 1) chose BRR 
for its simplicity and ability to 
trade-off the two effects. 
QALY26,27 Quality Adjusted Life 
Years 
A health-outcome index describing a 
patient’s level of health on several 
generic criteria and how an 
intervention might improve the 
states of health over time. 
None of the teams applied QALYs 
or the Q-TWiST approach because 
their focus on specific health 
outcomes does not take into 
account the many favourable and 
unfavourable effects that make up 
the benefit-risk balance for the 
drugs modelled in PROTECT. 
Q-TWiST28,29 Quality-adjusted Time 
Without Symptoms 
and Toxicity 
A combination of QALYs from three 
states of a patient undergoing 
cancer therapy. 
INHB30-32 Incremental Net 
Health Benefit 
An extension of QALYs that looks at 
the difference between benefits of 
two treatment options minus the 
difference between risks.  
As INHB is defined at present only 
for cancer treatments, it was not 
applicable to any of the drugs 
considered in PROTECT. 
Estimation techniques 
PSM33, 34 Probabilistic 
Simulation Method 
Uncertainty about each of the 
effects is represented by a 
probability distribution; Monte Carlo 
analysis shows the benefit-risk 
balance distribution for each drug 
and for the drug-comparator 
difference. 
All wave 2 case studies chose this 
technique to see its impact on the 
benefit-risk balance, to explore 
scenarios about the effects that 
could not be seen in the 
deterministic models and to 
accommodate uncertainties of 
lower-quality data.   
ITC/MTC35-37 Indirect Treatment 
Comparison/Mixed 
Treatment 
Comparison 
Compares two treatment effects 
where direct evidence is unavailable.  
Uses the link of each treatment to 
the placebo for calculating the 
variance of the difference in effects.  
Natalizumab and Rimonabant 
chose ITC/MTC in wave 2 either to 
deal with the heterogeneity of the 
data sources or to enable 
comparison with other active 
treatments. 
Utility survey technique 
DCE38-40 Discrete Choice 
Experiment 
Effect weights are derived from a 
person’s preferences between pairs 
of combinations of health levels 
across favourable and unfavourable 
effects.  Requires thinking about 
trade-offs between the effects. 
Only Rimonabant used DCE, and 
this was to elicit preferences from 
patients. 
Table 1.  The 13 methodologies, their features and an explanation of how they were used in the case studies. 
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Drug Indication 
Efalizumab Moderate to severe plaque psoriasis 
Telithromycin Mild to moderate community-acquired pneumonia (CAP), acute exacerbation of 
chronic bronchitis (AECB), and acute sinusitis (ABS) in patients of 18 years and 
older, as well as tonsillitis/pharyngitis caused by Streptococcus pyogenes in 
adults and adolescents, as an alternative when beta-lactam antibiotics are not 
appropriate 
Natalizumab Relapsing remitting multiple sclerosis 
Rimonabant Weight loss in obese or overweight patients with co-morbidities 
Rosiglitazone 
+ metformin 
Type II diabetes 
Warfarin Ischemic stroke in patients with atrial fibrillation 
Table 2.  Drugs forming the basis of the PROTECT Benefit-Risk case studies 
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Figure 1.  The structure and critical path for applying the methods in the case studies. (a) generic template, (b) efalizumab case study. 
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Figure 2.  A tree diagram for the efalizumab example.  The same tree was used in the descriptive PrOACT-URL and BRAT frameworks, and 
with the quantitative MCDA methodology.  See Table 3 for an explanation of the abbreviations used. 
 
 Name Description Units Raptiva Placebo 
Fa
vo
u
ra
b
le
 
Ef
fe
ct
s 
PASI75 Percentage of patients achieving 75% 
reduction in baseline PASI1 at week 12.  
% 29.5 2.7 
PGA Percentage of patients achieving 
Physician's Global Assessment2 
clear/almost clear at week12.  
% 29.5 5.1 
DLQI Dermatology Life Quality Index3. Mean 
change from base score. 
Change 
score 
5.8 2.1 
U
n
fa
vo
u
ra
b
le
 
Ef
fe
ct
s 
Severe 
infections 
Proportion of patients experiencing 
infections serious enough to require 
hospitalisation. 
%/100 
ptyrs 
2.83 1.4 
PML Number of cases of progressive 
multifocal leukoencephalopathy. 
 
number 3 0 
1PASI is a measure of the average redness, thickness and scaliness of the lesions (each graded on a 0-
4 scale), weighted by the body region and the area affected. PASI range is from 0 to 72. 
2PGA is a seven point scale with 7 being clear, 6 almost clear, 5 mild, 4 mild to moderate, 3 moderate, 
2 moderately severe and 1 severe psoriasis. 
3DLQI is a 10-item quality of life index scored by the patient on a four-point scale (0-3). 
 
Table 3.  Effects table for the efalizumab example. 
                                                                                 Pharmacoepidemiological Research on Outcomes of 
Therapeutics by a European ConsorTium 
                                         
 
       
20 
Recommended visualisations:
Effects table
Forest plot 
Start
Collect data
Classify evidence
Identify favourable 
and unfavourable 
effects
Present data on key 
effects for each 
alternative
Is one 
alternative 
clearly 
best?
Qualitative BR 
assessment
Judge relative value of 
benefits and risks
Is one 
alternative 
clearly most 
preferred?
Semi-
quantitative BR 
assessment
Aggregate effects data and 
value judgements explicitly
Quantitative BR 
assessment
NO
NO
YES
YES
Recommended 
methods:
PrOACT-URL
BRAT
ITC/MTC (for indirect 
evidence)
Recommended methods:
MCDA
wNCB (where all endpoints are binary and 
there are only 2 alternatives)
Recommended method:
MCDA
 
Figure 3.  Flowchart indicating the difference between quantitative and qualitative benefit-risk assessments, with recommended methods 
 
Figure 4.  Results of a quantitative analysis (using MCDA) for the efalizumab example.  The difference display shows the contribution of the 
weighted difference between drug and placebo for each effect.  Right-extending (green) bars favour the drug and left-extending (red) bars 
favour the placebo, for a 17.5 total difference (out of 100) in favour of efalizumab. 
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Figure 5.  Sensitivity analysis for the efalizumab case study, showing the effect of changing the weight on the PML criterion in MCDA.  The 
vertical red line represents the current weight of 18.5 (out of a total of 100 for all five criteria). The intersections of that line with the 
slanting red and green lines define the 17.5 difference noted in Figure 4.  If the PML weight is increased beyond 32, then the benefit-risk 
balance favours the placebo. 
1: Efalizumab 
2: Placebo 
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Figure 6.  The five-stage Roadmap and Recommendations for benefit-risk assessments 
 
IMI PROTECT Benefit-Risk Assessment Roadmap and Recommendations 
 
3. Analysis 
5. Conclusion and 
Dissemination 
4. Exploration 
2. Evidence Gathering 
and Data preparation 
1. Planning 
 
1- Planning: We recommend using a descriptive framework such as BRAT or PrOACT-URL to structure each 
benefit-risk assessment.  A set of benefits and risks should be chosen that covers the full range of treatment 
effects, and represented visually using a tree diagram to indicate the hierarchy.  A table template (‘effects table’ 
or ‘source table’) should be prepared, to represent the data that are required to be collected. 
2- Evidence Gathering and Data Preparation: Assessors should review all available evidence and select data that 
are sufficient to and appropriate for the decision problem.  The table template must be completed highlighting 
where data are available or missing for example by colour-coding missing data. The tree diagram and table 
produced initially may need to be revised in the light of available data. 
3- Analysis: The analysis should be appropriate to the complexity of the task.  Simple descriptive methods may 
suffice for everyday benefit-risk assessments, while quantitative decision models can provide additional clarity for 
more complex problems.  When a quantitative benefit-risk assessment approach is used, stakeholders’ value 
preferences and the benefit-risk magnitudes (by criteria and overall) should be represented by suitable bar graphs 
(particularly useful is the ‘difference display’), dot plots or line graphs to promote accurate point reading, local 
and global comparisons, and judging trade-offs among alternatives.  Care should be taken to avoid double 
counting events or effects in any analysis. 
4- Exploration:  All benefit-risk assessments should include a sensitivity analysis of some kind.  Where benefits and 
risks are finely balanced, quantitative decision models facilitate the execution and communication of sensitivity 
analyses by clearly setting out the respective impacts of effects uncertainty and preference uncertainty on the 
results.  The visual representations which should be used at this stage are distribution plots, line graphs, forest 
plots or tornado plots to provide comprehensive overview of the benefit-risk analysis allowing better-informed 
decisions. 
5- Conclusion and dissemination:  Adopting a formal structure for a benefit-risk assessment is an effective way to 
improve the overall transparency and communicability of the process and facilitate robust decision making. 
 
